← All trials
NCT04601935
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 9, 2020
- Primary completion
- Jan 31, 2023
- Completion date
- Oct 31, 2024
- First posted
- Oct 26, 2020
- Last posted
- Oct 26, 2020
- Enrollment
- 34
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai Changzheng HospitalLead sponsor
- Second Military Medical UniversitySponsor investigator
- GenScriptCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.